| Ac-225 rosopatamab tetraxetan (CONV01-α) / Dominari Holdings |
CONVERGE-01, NCT06549465: Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer |
|
|
| Recruiting | 2 | 47 | US | In-111 rosopatamab tetraxetan, 45 KBq/kg Ac-225 rosopatamab tetraxetan, 55 KBq/kg Ac-225 rosopatamab tetraxetan, 60 KBq/kg Ac-225 rosopatamab tetraxetan | Convergent Therapeutics | PSMA PET-Positive Castration-Resistant Prostate Cancer | 12/25 | 04/27 | | |
NCT04886986: Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer |
|
|
| Suspended | 1/2 | 48 | US | 225Ac-J591, 177Lu-PSMA-I&T, 177Lu-PNT2002, 68Ga-PSMA-11, 68Ga-PSMA-HBED-CC | Weill Medical College of Cornell University, POINT Biopharma | Prostate Cancer | 12/25 | 12/27 | | |
NCT04946370: Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer |
|
|
| Recruiting | 1/2 | 76 | US | 225Ac-J591, Pembrolizumab, Androgen receptor pathway inhibitor, 68Ga-PSMA-11, 68Ga-PSMA-HBED-CC | Weill Medical College of Cornell University, United States Department of Defense, Merck Sharp & Dohme LLC | Prostate Cancer | 06/26 | 06/28 | | |
NCT04506567: Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC |
|
|
| Suspended | 1/2 | 105 | US | 225Ac-J591, 68Ga-PSMA-HBED-CC injection, 68Ga-PSMA-11 | Weill Medical College of Cornell University | Prostate Cancer | 06/25 | 06/27 | | |
| Completed | 1 | 32 | US | 225Ac-J591, 68Ga-PSMA-HBED-CC injection for PET/CT Scan on day 1 and at end of study | Weill Medical College of Cornell University, Prostate Cancer Foundation, United States Department of Defense, National Institutes of Health (NIH), National Cancer Institute (NCI) | Prostate Cancer | 01/21 | 09/23 | | |
ACTION, NCT05567770: ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer |
|
|
| Withdrawn | 1 | 24 | NA | Actinium-J591, Stereotactic Body Radiation Therapy, SBRT, Androgen Deprivation Therapy, ADT | Weill Medical College of Cornell University, Convergent Therapeutics, Inc. | Prostate Cancer Metastatic | 01/25 | 01/30 | | |
| Active, not recruiting | 1 | 6 | US | 225Ac-J591, 68Ga-PSMA-HBED-CC injection for PET/CT Scan at screening, week 12 and week 24 | Weill Medical College of Cornell University | Prostate Cancer | 12/25 | 12/26 | | |
